BuZhong YiQi Formula (BZYQF) can alleviate type 2 diabetes mellitus (T2DM). However, its efficacy in managing postprandial hyperglycemia in T2DM needs to be further confirmed, and its underlying mechanism and pharmacodynamic material basis have not been sufficiently investigated. A T2DM rat model was induced to measure postprandial glycemic responses following glucose and starch ingestion. In vitro assays of enzymatic inhibition and the kinetic mode were performed to evaluate the inhibitory effect of BZYQF on α-amylase and α-glucosidase activities. The main constituent contents of BZYQF in a simulated digestion assay were measured to screen the active constituents in BZYQF against α-amylase and α-glucosidase activities via Pearson correlation and multiple linear regression analyses. Finally, the total flavonoids were purified from BZYQF to perform in vitro activity validation, and the flavonoid constituent activity was verified through molecular docking. In vivo assays showed that BZYQF significantly reduced the blood glucose values of CON rats but not T2DM rats after glucose ingestion, while BZYQF significantly reduced the blood glucose levels by 15 min after starch ingestion in CON and T2DM rats, with more significant decreases in blood glucose levels in T2DM rats. In vitro enzymatic assays showed that BZYQF could inhibit the activities of α-amylase and α-glucosidase in competitive and non-competitive modes and in an uncompetitive mode, respectively. Furthermore, BZYQF showed a stronger inhibitory effect on α-glucosidase activity than on α-amylase activity. Simulated digestion showed that simulated gastric fluid and intestinal fluid changed the main constituent contents of BZYQF and their inhibition rates against α-amylase and α-glucosidase activities, and similar results were rarely found in simulated salivary fluid. Pearson correlation and multiple linear regression analyses revealed that the total flavonoids were the active constituents in BZYQF inhibiting α-amylase and α-glycosidase activities. This result was verified by examining the total flavonoids purified from BZYQF. A total of 1909 compounds were identified in BZYQF using UPLC-MS/MS, among which flavones were the most abundant and consisted of 467 flavonoids. Molecular docking showed that flavonoids in BZYQF were bound to the active site of α-amylase, while they were bound to the inactive site of α-glucosidase. This result supported the results of the enzyme kinetic assay. BZYQF significantly alleviated postprandial hyperglycemia in T2DM rats by inhibiting α-amylase and α-glycosidase activities, in which flavonoids in BZYQF were the active constituents.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11858844 | PMC |
http://dx.doi.org/10.3390/ph18020201 | DOI Listing |
Cureus
February 2025
Department of Pharmacology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, IND.
Background: The rising prevalence of type II diabetes mellitus (T2DM) has increased the risk of hepatic dysfunction, necessitating effective therapeutic interventions. Natural products, particularly (BA) and (WS), are known for their hepatoprotective properties.
Objectives: This study investigates the hepatoprotective effects of BA, WS, and their polyherbal combination in streptozotocin-nicotinamide-induced T2DM in Wistar rats.
J Asian Nat Prod Res
March 2025
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing210023, China.
This study aimed to explore the potential mechanism of Xiexin Tang in improving type 2 diabetes mellitus from the perspective of intestinal barrier function. The results indicated that Xiexin Tang could notably promote the expression of GPRs while suppressing the expression of HDACs in colon epithelial cells, then significantly elevate the levels of TGF-β1 and IL-18 to regulate the differentiation of T cells and further maintain the intestinal immune homeostasis. Meanwhile, it could markedly inhibit the inflammatory signaling pathway to improve intestinal barrier function, relieving type 2 diabetes mellitus.
View Article and Find Full Text PDFGut Microbes
December 2025
Department of General Surgery, Daping Hospital, Army Medical University, Chongqing, China.
Roux-en-Y gastric bypass (RYGB) results in glucose-lowering in patients with type 2 diabetes mellitus (T2DM) and may be associated with increased intestinal glucose excretion. However, the contribution of intestinal glucose excretion to glycemic control after RYGB and its underlying mechanisms are not fully elucidated. Here, we confirmed that intestinal glucose excretion significantly increased in obese rats after RYGB, which was negatively correlated with postoperative blood glucose levels.
View Article and Find Full Text PDFDiabetes Metab Syndr Obes
February 2025
Department of Endocrinology Two, the First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui Province, 230031, People's Republic of China.
Background: Shenzhu Tiaopi granule (STG) has antidiabetic functions. Data-independent acquisition proteomic technology is an integral part of systems biology. Herein, proteomics was used to analyse the effects of STG on type 2 diabetes mellitus (T2DM) and the mechanism by which STG normalizes glucose metabolism.
View Article and Find Full Text PDFJ Musculoskelet Neuronal Interact
March 2025
Department of Orthopedics, Affiliated Hospital of Youjiang Medical University for Nationalities, Guangxi Key Laboratory for Biomedical Materials Research, Guangxi, China.
Objectives: This study investigated the therapeutic effects of stigmasterol (STG), derived from , on osteoporosis in rats with type 2 diabetes mellitus (T2DM).
Methods: Twenty-four Male Sprague-Dawley rats (6 weeks old) were used to establish a T2DM model and were divided into four groups: normal diet (ND), high-fat diet (HFD), low-dose STG (STG-L, 100 mg/kg), and high-dose STG (STG-H, 200 mg/kg). The rats received daily gavage treatments for four weeks.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!